The generalizability of psychotherapy efficacy trials in major depressive disorder: an analysis of the influence of patient selection in efficacy trials on symptom outcome in daily practice

BMC Psychiatry

Frans G Zitman⁴  Pim Cuijpers²  Tineke van Veen⁴  Nic JA van der Wee³  Wouter WH de Wever⁴  Rosalind van der Lem¹ 

[1] Kijvelanden/Het Dok, Zomerhofstraat 76-90, Rotterdam, CM 3032, The Netherlands;Department of Clinical Psychology, VU University, Van der Boechorststraat 1, Amsterdam, BT, 1081, the Netherlands;Leiden Institute for Brain and Cognition, Albinusdreef 2, PO box 9600, Leiden, RC, The Netherlands;Department of Psychiatry, Leiden University Medical Center/Rivierduinen, Albinusdreef 2, PO box 9600, Leiden, RC, The Netherlands

关键词: Routine outcome monitoring;    Routine clinical practice;    Symptom outcome;    Treatment outcome;    Generalizability;    Exclusion criteria;    Psychotherapy efficacy trials;    Major depressive disorder;   

Others  :  1124240
DOI  :  10.1186/1471-244X-12-192

 received in 2012-02-29, accepted in 2012-10-25,  发布年份 2012

【 摘 要 】

Background

Treatment guidelines for major depressive disorder (MDD) are based on results from randomized clinical trials, among others in psychotherapy efficacy trials. However, patients in these trials differ from routine practice patients since trials use stringent criteria for patient selection. It is unknown whether the exclusion criteria used in psychotherapy efficacy trials (PETs) influence symptom outcome in clinical practice. We first explored which exclusion criteria are used in PETs. Second, we investigated the influence of commonly used exclusion criteria on symptom outcome in routine clinical practice.

Methods

We performed an extensive literature search in PubMed, PsycInfo and additional databases for PETs for MDD. From these, we identified commonly used exclusion criteria. We investigated the influence of exclusion criteria on symptom outcome by multivariate regression models in a sample of patients suffering from MDD according to the MINIplus from a routine clinical practice setting (n=598). Data on routine clinical practice patients were gathered through Routine Outcome Monitoring.

Results

We selected 20 PETs and identified the following commonly used exclusion criteria: ‘a baseline severity threshold of HAM-D≤14’, ‘current or past abuse or dependence of alcohol and/or drugs’ and ‘previous use of medication or ECT’. In our routine clinical practice sample of patients suffering from MDD (n=598), presence of ‘current or past abuse of or dependence on alcohol and/or drugs’ had no significant influence on outcome.‘Meeting a baseline severity threshold of HAM-D≤14’ and ‘previous use of medication or ECT’ were associated with better outcome, but the explained variance of the models was very small (R²=2-11%).

Conclusions

The most consistently used exclusion criteria are not a major threat to the generalizability of results found in PETs. However, PETs do somewhat improve their results by exclusion of patients with minor depression and patients who used antidepressants prior to psychotherapy.

【 授权许可】

   
2012 van der Lem et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Zimmerman M, Mattia JI, Posternak MA: Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002, 159:469-473.
• [2]Zimmerman M, Chelminski I, Posternak MA: Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included. J Nerv Ment Dis 2004, 192:87-94.
• [3]Zetin M, Hoepner CT: Relevance of exclusion criteria in antidepressant clinical trials: a replication study. J Clin Psychopharmacol 2007, 27:295-301.
• [4]Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003, 290:1624-1632.
• [5]Wells KB: Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research. Am J Psychiatry 1999, 156:5-10.
• [6]Partonen T, Sihvo S, Lonnqvist JK: Patients excluded from an antidepressant efficacy trial. J Clin Psychiatry 1996, 57:572-575.
• [7]van der Lem R, van der Wee NJ, Van VT, Zitman FG: The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice. Psychol Med 2011, 41:1353-1363.
• [8]Wisniewski SR, Rush AJ, Nierenberg AA, Gaynes BN, Warden D, Luther JF, et al.: Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry 2009, 166:599-607.
• [9]Lem R, Stamsnieder P, Wee N, Veen T, Zitman FG: Socio-demographic features in randomized controlled trials for major depression: generalizability and individualization. Int J Person Cent Medicine 2011, 1:268-278.
• [10]Stirman SW, Derubeis RJ, Crits-Christoph P, Rothman A: Can the randomized controlled trial literature generalize to nonrandomized patients? J Consult Clin Psychol 2005, 73:127-135.
• [11]Stirman SW, Derubeis RJ, Crits-Christoph P, Brody PE: Are samples in randomized controlled trials of psychotherapy representative of community outpatients? A new methodology and initial findings. J Consult Clin Psychol 2003, 71:963-972.
• [12]de Beurs E, den Hollander-Gijsman ME, van Rood YR, van der Wee NJ, Giltay EJ, van Noorden MS, et al.: Routine outcome monitoring in the Netherlands: practical experiences with a web-based strategy for the assessment of treatment outcome in clinical practice. Clin Psychol Psychother 2011, 18:1-12.
• [13]Karasu T, Gelenberg AJ, Merriam A, Wang P: Practice guidelines for the treatment of patients with major depressive disorder. Second edition. American Psychiatric Association; 2000.
• [14]Anderson I, Pilling S, Barnes A, Bayliss L, Bird V: The NICE guideline on the treatment and management of depression in adults. London: The British Psychological Society & The Royal College of Psychiatrists; Updated version 2010. 1-1-2009
• [15]National Taskforce Guideline: Multidisciplinary guidelines for diagnostics and treatment of adult patients with major depressive disorder. The Netherlands: Stuurgroep Richtlijnen/ Trimbos Institute; revised version. 1-1-2005
• [16]Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al.: The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 20(59 Suppl):22-33.
• [17]Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G: A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl 1978, 5-27.
• [18]Posternak MA, Zimmerman M, Keitner GI, Miller IW: A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry 2002, 159:191-200.
• [19]Lem R, Wee N, Veen T, Zitman FG: The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice. Psychol Med 2010.
• [20]Zimmerman M, Chelminski I, Posternak M: A review of studies of the montgomery-asberg depression rating scale in controls: implications for the definition of remission in treatment studies of depression. Int Clin Psychopharmacol 2004, 19:1-7.
• [21]McLean PD, Hakstian AR: Clinical depression: comparative efficacy of outpatient treatments. J Consult Clin Psychol 1979, 47:818-836.
• [22]Gardner P, Oei TP: Depression and self-esteem: an investigation that used behavioral and cognitive approaches to the treatment of clinically depressed clients. J Clin Psychol 1981, 37:128-135.
• [23]Garvey MJ, Hollon SD, Derubeis RJ: Do depressed patients with higher pretreatment stress levels respond better to cognitive therapy than imipramine? J Affect Disord 1994, 32:45-50.
• [24]Kovacs M, Rush AJ, Beck AT, Hollon SD: Depressed outpatients treated with cognitive therapy or pharmacotherapy. A one-year follow-up. Arch Gen Psychiatry 1981, 38:33-39.
• [25]Simons AD, Garfield SL, Murphy GE: The process of change in cognitive therapy and pharmacotherapy for depression. Changes in mood and cognition. Arch Gen Psychiatry 1984, 41:45-51.
• [26]Sotsky SM, Glass DR, Shea MT, Pilkonis PA, Collins JF, Elkin I, et al.: Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH treatment of depression collaborative research program. Am J Psychiatry 1991, 148:997-1008.
• [27]Weissman MM, Prusoff BA, DiMascio A, Neu C, Goklaney M, Klerman GL: The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. Am J Psychiatry 1979, 136:555-558.
• [28]Beck AT, Hollon SD, Young JE, Bedrosian RC, Budenz D: Treatment of depression with cognitive therapy and amitriptyline. Arch Gen Psychiatry 1985, 42:142-148.
• [29]Blackburn IM, Bishop S, Glen AI, Whalley LJ, Christie JE: The efficacy of cognitive therapy in depression: a treatment trial using cognitive therapy and pharmacotherapy, each alone and in combination. Br J Psychiatry 1981, 139:181-189.
• [30]Blom MB, Jonker K, Dusseldorp E, Spinhoven P, Hoencamp E, Haffmans J, et al.: Combination treatment for acute depression is superior only when psychotherapy is added to medication. Psychother Psychosom 2007, 76:289-297.
• [31]Derubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, Salomon RM, et al.: Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005, 62:409-416.
• [32]DiMascio A, Weissman MM, Prusoff BA, Neu C, Zwilling M, Klerman GL: Differential symptom reduction by drugs and psychotherapy in acute depression. Arch Gen Psychiatry 1979, 36:1450-1456.
• [33]Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis ME, et al.: Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol 2006, 74:658-670.
• [34]Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, et al.: National institute of mental health treatment of depression collaborative research program. General effectiveness of treatments. Arch Gen Psychiatry 1989, 46:971-982.
• [35]Hollon SD, Derubeis RJ, Evans MD, Wiemer MJ, Garvey MJ, Grove WM, et al.: Cognitive therapy and pharmacotherapy for depression. Singly and in combination. Arch Gen Psychiatry 1992, 49:774-781.
• [36]Luty SE, Carter JD, McKenzie JM, Rae AM, Frampton CM, Mulder RT, et al.: Randomised controlled trial of interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatry 2007, 190:496-502.
• [37]McBride C, Atkinson L, Quilty LC, Bagby RM: Attachment as moderator of treatment outcome in major depression: a randomized control trial of interpersonal psychotherapy versus cognitive behavior therapy. J Consult Clin Psychol 2006, 74:1041-1054.
• [38]Murphy GE, Simons AD, Wetzel RD, Lustman PJ: Cognitive therapy and pharmacotherapy. Singly and together in the treatment of depression. Arch Gen Psychiatry 1984, 41:33-41.
• [39]Murphy GE, Carny RM, Knesevich MA, Wetzel RD, Whitworth P: Cognitive behavior therapy, relaxation training and tricyclic antidepressant medication in the treatment of depression. Psychol Rep 1995, 77(2):403-420.
• [40]Rush AJ, Beck AT, Kovacs M, Hollon SD: Comparative efficacy of cognitive therapy and pharmocotherapy in the treatment of depressed outpatients. 1977, 17-37. [Cognitive therapy and research]
• [41]Strauman TJ, Vieth AZ, Merrill KA, Kolden GG, Woods TE, Klein MH, et al.: Self-system therapy as an intervention for self-regulatory dysfunction in depression: a randomized comparison with cognitive therapy. J Consult Clin Psychol 2006, 74:367-376.
• [42]Teri L, Lewinsohn PM: Individual and group treatment of unipolar depression: comparison of treatment outcome and identification of predictors of succesful treatment outcome. Behav Ther 1986, 7:215-228.
• [43]Watson JC, Gordon LB, Stermac L, Kalogerakos F, Steckley P: Comparing the effectiveness of process-experiential with cognitive-behavioral psychotherapy in the treatment of depression. J Consult Clin Psychol 2003, 71:773-781.
• [44]Wilson PH: Combined pharmacological and behavioural treatment of depression. Behav Res Ther 1982, 20:173-184.
• [45]Wilson PH, Goldin JC, Charbonneaupowis M: Comparative efficacy of behavioral and cognitive treatments of depression. 7th edition. 1983, 111-124. [Cognitive therapy and research]
• [46]Wright JH, Wright AS, Albano AM, Basco MR, Goldsmith LJ, Raffield T, et al.: Computer-assisted cognitive therapy for depression: maintaining efficacy while reducing therapist time. Am J Psychiatry 2005, 162:1158-1164.
• [47]Zettle RD, Haflich JL, Reynolds RA: Responsivity to cognitive therapy as a function of treatment format and client personality dimensions. J Clin Psychol 1992, 48:787-797.
• [48]Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967, 6:278-296.
• [49]Zimmerman M, Posternak MA, Chelminski I: Derivation of a definition of remission on the Montgomery-Asberg depression rating scale corresponding to the definition of remission on the Hamilton rating scale for depression. J Psychiatr Res 2004, 38:577-582.
• [50]Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D, et al.: The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006, 16:601-611.
• [51]Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, et al.: Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 2007, 164:739-752.
• [52]van der Lem R, van der Wee NJ, Van VT, Zitman FG: Efficacy versus effectiveness: a direct comparison of the outcome of treatment for mild to moderate depression in randomized controlled trials and daily practice. Psychother Psychosom 2012, 81:226-234.
• [53]Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
• [54]Leonard KL: Is patient satisfaction sensitive to changes in the quality of care? An exploitation of the Hawthorne effect. J Health Econ 2008, 27:444-459.
• [55]Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al.: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
• [56]Jacobson NS, Truax P: Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991, 59:12-19.